{"id":"ceftolozane-tazobactam-meropenem","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Seizures (rare, carbapenem-associated)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftolozane is a fifth-generation cephalosporin with enhanced activity against Pseudomonas aeruginosa and gram-negative bacteria, while tazobactam is a beta-lactamase inhibitor that prevents enzymatic degradation of the beta-lactams. Meropenem is a broad-spectrum carbapenem that provides additional coverage against resistant gram-negative and gram-positive organisms. Together, this triple combination targets multiple resistance mechanisms and provides synergistic antimicrobial activity.","oneSentence":"This combination inhibits bacterial cell wall synthesis through dual beta-lactam action (ceftolozane-tazobactam and meropenem) while tazobactam protects against beta-lactamase resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:52.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Hospital-acquired and ventilator-associated bacterial pneumonia"},{"name":"Complicated urinary tract infections"},{"name":"Multi-drug resistant gram-negative infections"}]},"trialDetails":[{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06342115","phase":"PHASE4","title":"Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","status":"RECRUITING","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2025-03-26","conditions":"Febrile Neutropenia","enrollment":176},{"nctId":"NCT05566665","phase":"","title":"Nosocomial Infections in ECMO Patients","status":"RECRUITING","sponsor":"Policlinico Hospital","startDate":"2023-01-01","conditions":"Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication","enrollment":200},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT03217136","phase":"PHASE2","title":"MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":94},{"nctId":"NCT03230838","phase":"PHASE2","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-26","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":134},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT04238390","phase":"PHASE3","title":"Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2022-01","conditions":"Bacteremia Caused by Gram-Negative Bacteria","enrollment":""},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftolozane-tazobactam + Meropenem","genericName":"Ceftolozane-tazobactam + Meropenem","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits bacterial cell wall synthesis through dual beta-lactam action (ceftolozane-tazobactam and meropenem) while tazobactam protects against beta-lactamase resistance. Used for Complicated intra-abdominal infections, Hospital-acquired and ventilator-associated bacterial pneumonia, Complicated urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}